1	Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert® Mpox					
2	(Cepheid®) and STANDARD™ M10 MPX/OPX (SD Biosensor) molecular point-of-care assays					
3	for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab samples.					
4	Alessandra Romero-Ramirez ^a , Anushri Somasundaran ^a , Konstantina Kontogianni ^a , Jacob Parkes ^a ,					
5	Yusra Hussain ^a , Susan Gould ^{b,c} , Christopher T Williams ^a , Dominic Wooding ^a , Richard Body ^d , Hayley					
6	E Hardwick ^e , J Kenneth Baillie ^f , Jake Dunning ^{g,h} , Malcom G Semple ^e , CONDOR steering group,					
7	ISARIC CCP UK investigators, Tom E Fletcher ^{b,c} , Thomas Edwards ^a , Devy Emperador ⁱ , and Ana I					
8	Cubas-Atienzar ^a .					
9						
10	^a Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, UK					
11	^b Department of Clinical Sciences, Liverpool School of Tropical Medicine, UK					
12	^c Royal Liverpool University Hospital NHS Foundation Trust, UK					
13	^d Manchester University NHS Foundation Trust, UK					
14	^e NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Department of Clinical					
15	Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences,					
16	University of Liverpool, Liverpool, UK					
17	^f Baillie Gifford Pandemic Science Hub, Institute for Regeneration and Repair, University of					
18	Edinburgh					
19	^g Pandemic Sciences Institute, University of Oxford, UK					
20	^h Infectious Diseases Department, Royal Free London NHS Foundation Trust, London, UK					
21	ⁱ Foundation of Innovative Diagnostics, Geneva, Switzerland					
22 23	Address correspondence to Dr Ana Cubas-Atienzar, email: <u>Ana.CubasAtienzar@lstmed.ac.uk</u>					
24						
25	Highlights					
26						
27	• The Xpert® Mpox detected Monkeypox virus (MPXV) DNA in more samples than the M10					
28	NOTE: THIS PREY/OPEX, CDC aPCR and Sansure, aPCR suggesting higher sensitivity at lower viral loads.					

29	• Xpert® Mpox fulfilled the performance requirements recommended in the World Health						
30	Organisation (WHO) target product profile (TPP) using upper-respiratory swabs (URS) and						
31	skin lesion swabs (SS) but M10 MPX/OPX performance was only met when using SS.						
32	• MPXV DNA was reliably detectable in SS up to 5 days after onset of symptoms.						
33	with all PCR tests						
34	• The use of URS for mpox diagnosis is not recommended for use more than 3 days after onset						
35	of symptoms.						
36	Abstract						
37	Objectives						
38	Evaluation of diagnostic accuracy of two point-of-care (POC) molecular diagnostic tests for the						
39	detection of monkeypox virus (MPXV): Xpert® Mpox (Cepheid, Inc., USA) and STANDARD™						
40	M10 MPX/OPX (SD Biosensor, Inc., Korea).						
41	Methods						
42	Diagnostic accuracy of both platforms was evaluated using 53 upper-respiratory swabs (URS) and 32						
43	skin lesions swabs (SS) collected from mpox and COVID-19 patients in the UK against the Sansure						
44	(Sansure Biotech Inc.) and the CDC reference qPCR tests. The analytical sensitivity of both platforms						
45	was assessed using a viral isolate from the lineage II, B.1.						
46	Results						
47	The limit of detection was $1x10^{1}$ pfu/ml for both tests. The overall sensitivity and specificity of the						
48	Xpert® Mpox was 97.67% [95% CI 87.71–99.94%] and 88.57% [95% CI 73.26–96.80%] and 97.44%						
49	[95% CI 86.52–99.94%] and 74.42% [95% CI 58.83–86.48%] comparing the Sansure and CDC qPCR,						
50	respectively and for the M10 MPX/OPX was 87.80% [95% CI 73.80-95.92%] and 76.60% [95% CI						
51	61.97-87.70%] and 94.29% [95% CI 80.84-99.30%] and 86.67% [95% CI 73.21-94.95%] with the						
52	Sansure and CDC qPCR.						
53	Conclusion						

54 The Xpert® Mpox had good diagnostic accuracy for both sample types while the M10 MPX/OPX

55 clinical accuracy was deficient with URS. Our data supports the use of URS during the first 3 days of

56 symptoms onset for mpox diagnosis.

57 Keywords: mpox, MPXV, point-of-care (POC), diagnostics, PCR, Monkeypox, Orthopoxvirus,

58

59 Introduction

The highly infectious monkeypox virus (MPXV) is a double-stranded DNA virus belonging to the *Orthopoxviridae* family, which includes vaccinia, cowpox, and variola viruses¹. Orthopoxviruses are large viruses with a size range from 140-450 nanometers and a genome that contains over 200 genes². MPXV was identified in 1958 in captive cynomolgus macaques (*Macaca fascicularis*) that were transported from Singapore to Denmark³ and in 1970, the first known case of MPXV infection in a human from the Democratic Republic of the Congo (DRC) was reported⁴. The WHO recommended "Mpox" as the preferred term for human disease caused by MPXV in November 2022⁵.

67 In May 2022, an mpox outbreak spread to over 110 countries with over 86,000 confirmed cases⁶. The number of infections during the 20th century has already been surpassed by cases after the 2022 68 69 outbreak⁷. At that time, in the United Kingdom (UK), all clades of mpox were classified as a High 70 Consequence Infectious Disease (HCID) and patients were looked after in specially designed HCID 71 treatment facilities run by a nationwide network⁸. From August 2018 to September 2021, 7 mpox cases 72 were identified in the UK and received treatment in HCID centres (4 imported cases and 3 secondary 73 cases)⁸. The discovery of the first mpox case of the global outbreak was on May 7, 2022, a person who 74 travelled from Nigeria⁹ and as of June 8, 2022, there were 336 laboratory-confirmed cases in the UK. Most of these cases were identified in men [99%], who were primarily residents of London [81%]¹⁰. 75 76 For the first time, community transmission was reported in the UK, which was mainly through intimate 77 person-to-person contact, often involving sexual activity and mostly unrelated to travel from endemic 78 countries¹¹.

Clinical manifestations of mpox infection include a vesiculopustular rash resembling that of smallpox,
fevers, lymphadenopathy and a rash may affect palms and soles. Skin lesions may commence at the site

81 of initially inoculation or exposure e.g. the anogenital region after transmission during sexual contact 82 or at the site of a needlestick injury or bite¹². According to the Centres for Disease Control and 83 Prevention (CDC), the incubation period is up to 21 days following/after viral exposure and the rash 84 appears 1-4 days after initial flu-like prodrome¹³. To confirm a clinical diagnosis, the World Health 85 Organisation (WHO) advises testing for mpox as soon as possible in people who fit the suspected case 86 definition¹⁴. Laboratory-based nucleic acid amplification tests (NAAT) are the primary method used 87 for mpox diagnosis¹⁵. Laboratory-based PCR testing requires specialist equipment, up front DNA 88 extraction, and skilled personnel to perform such tests. Many cases in low- and middle-income countries 89 (LMIC) remain unreported due to a lack of decentralised diagnostic resources in the area, and issues 90 with the current healthcare system and civil upheaval.

91 The increasing global cases of mpox following the 2022 outbreak brought to light the difficulties in 92 meeting the increased and erratic demand of decentralised diagnostics for different virus prone to 93 outbreaks. Another public health emergency of international concern (PHEIC) was declared by WHO 94 on 14th August 2024 given the significant increase in mpox cases which has the potential to spread 95 beyond Africa¹⁶. This highlighted the urgent need for the rational development of rapid diagnostic 96 methods for emerging pathogens such as for MPXV as a priority. As a result, several NAAT were developed to identify MPXV at the point-of-care (POC) since the 2022 outbreak^{17,18}. POC NAAT offer 97 98 higher sensitivity and specificity compared to antigen-based POC tests and are equal to laboratory-99 quality testing without the requirement for sophisticated laboratory facilities¹⁹, requiring less 100 operational training and fewer sample preparation steps compared to lab-based PCR.

101 Prompt isolation and optimal clinical care are all dependent on an accurate diagnosis of MPXV 102 infection. In this study, we evaluated the diagnostic accuracy of two new POC NAAT, Xpert® Mpox 103 (Cepheid, Inc., Sunnyvale, CA, USA) and STANDARD™ M10 MPX/OPX (SD Biosensor, Inc., 104 Suwon, Korea), for the detection of MPXV on skin lesion and upper-respiratory swabs.

105 Methodology

106 Study design

107 Skin lesion swabs (SS) (n=30) and upper-respiratory swab (URS) samples (n=23, [nasopharyngeal=1,

108 oropharyngeal=22]) in universal transport media (UTM, RT-UTM Copan, Italy) from a cohort of 16

109 mpox patients enrolled at the Royal Liverpool University Hospital, Sheffield Teaching Hospital NHS 110 Foundation Trust, and Royal London Hospital were used for this study. Patients were recruited during 111 the last two outbreaks of mpox in the UK, 2018 and 2022. Patients were consented under the WHO 112 ISARIC4 Comprehensive Clinical Characterisation Collaboration Protocol for severe emerging infections [ISRCTN66726260]²⁰, ethical approval was obtained from the National Research Ethics 113 114 Service and the Health Research Authority (IRAS ID:126600, REC 13/SC/0149). All mpox patients 115 were diagnosed by sending samples to the UK Health Security Agency (UKHSA) for testing using 116 qPCR. In addition to the samples from mpox positive patients, to fulfil with the minimum number of negative swab specimens for Mpox diagnostic evaluations recommended by the by the FDA¹⁵, a set of 117 32 leftover nasopharyngeal samples in UTM (RT-UTM Copan, Italy) from prior COVID-19 studies¹⁹⁻ 118 119 ²² were used as mpox negative controls. These were collected under the Facilitating AcceLerated Clinical validation Of Novel diagnostics for COVID-19^{19,23} and ethical approval was obtained from the 120 121 National Research Ethics Service and the Health Research Authority (IRAS ID:28422, REC: 122 20/WA/0169). All samples were aliquots stored at -80°C and thawed for the first time for this study. 123 Samples were processed and tested at the Biosafety Level 3 (BSL3) Laboratories of the Liverpool 124 School of Tropical Medicine (LSTM) as previously described¹⁹.

125 MPXV PCR reference assays

126 The DNA was extracted from 200µL of UTM using the QiAamp96 Virus Qiacube HT kit (Qiagen, 127 Germany). Two reference PCR tests were used, the commercially available CE-IVD Sansure qPCR kit 128 (Monkeypox virus Nucleic Acid Diagnostic Kit, Sansure Biotech Inc.), and the CDC Monkeypox virus 129 Generic Real-Time PCR Test²¹. Both lab-based PCR tests were used as reference tests as the CDC 130 qPCR is widely used, the Sansure qPCR kit is CE-IVD marked and both have successfully demonstrated to detect MPXV clades I, IIa and IIb^{22,23}. The PCRs were performed on the QuantStudio 5 131 132 (ThermoFisher, USA) following the manufacturer instructions (Sansure Biotech Inc.) and the CDC 133 guidelines²¹. The CDC qPCR was performed using the QuantiFast Pathogen PCR kit (Qiagen, 134 Germany).

135 MPXV POC index NAAT

136 Two rapid molecular POC platforms which perform automated sample processing and qPCR to detect 137 viral DNA were evaluated in the study: Xpert® Mpox and the STANDARD[™] M10 MPX/OPX (M10 138 MPX/OPX hereinafter). The platforms were selected following an expression of interest launched by 139 FIND (www.finddx.org) and a scoring process based on defined criteria. The evaluation of the 140 platforms at LSTM was done in BSL3 laboratories.

141 The Xpert® Mpox assay is authorized for use under FDA Emergency Use Authorization (EUA) and 142 provides semiquantitative detection and differentiation between MPXV clade II (two undisclosed 143 targets) and non-variola Orthopoxvirus (target OPXV-E9L NVAR gene) DNA, respectively²⁴. A 144 Sample Processing Control (SPC), a Sample Adequacy Control (SAC), and a Probe Check Control 145 (PCC, not included in the algorithm, used as quality control) are also included in the cartridge utilised by the GeneXpert® instrument²⁵. The tests were performed according to the manufacturer's 146 147 instructions. Briefly, 300uL sample were transferred to the sample chamber of the Xpert[®] Mpox test 148 cartridge and loaded onto the GeneXpert[®] Instrument System platform. The results were automatically interpreted by the GeneXpert® System based on the Ct values results. A sample was called positive 149 150 when it was positive for the 2 MPXV targets (OPXV, SAC, SPC could be either positive or negative); 151 negative result when it was negative for MPXV and OPXV but positive for SAC and SPC; a positive 152 result for non-variola OPXV when it was positive for the OPXV target, negative for MPXV (SAC and 153 SPC can be either positive or negative); and invalid when it was negative for both viral targets and 154 controls or when only one control was positive but both viral targets negative.

155 The M10 MPX/OPX assay is for Research Use Only and provides semiquantitative detection and 156 differentiation between MPXV and OPXV DNA using E9L and G2R gene targets, respectively. The 157 LOD as reported by the manufacturer is 100 copies/ml. The tests were performed according to 158 manufacturer's instructions. Briefly, 300µL of sample were transferred to the sample chamber of the 159 cartridge and loaded onto the STANDARDTM M10 platform. After 1 hour, the results with the 160 corresponding Ct values were displayed on the STANDARDTM M10 screen and the results were 161 automatically interpreted. A sample was considered positive for MPXV when MPXV and OPVX 162 targets were positive (IC can be either positive or negative), positive result for OPXV when MPXV was

163 negative and OPXV was positive (IC can be either positive or negative), negative when only the IC was

164 positive and invalid when all targets were negative or when only the MPXV target was positive.

165 Analytical limit of detection of qPCR reference assays and POC index NAATs

166 A MPXV strain (Slovenia MPXV-1 2022, isolate 2225/22 Slovenia ex Gran Canaria) from the lineage 167 II, B.1 (European Virus Archive Global EVAg, Marseille, France) was cultured in Vero C1008 168 (ECACC 85020206) (Vero E6 cells) obtained from the European collection of authenticated cell 169 cultures (ECACC) in Dulbecco's Modified Eagle Medium (DMEM, Gibco, USA) plus 10% foetal 170 bovine serum (FBS, Gibco, USA) and 1% Penicillin/Streptomycin solution (Gibco, USA) to generate 171 the MPXV stock. Frozen aliquots of the fourth passage of the virus were quantified via plaque assay. 172 The MPXV stock was used to investigate the limit of detection (LOD) of both Xpert® Mpox and M10 173 MPX/OPX assays. A fresh aliquot was serially diluted from 1.0×10^4 plaque forming units (pfu)/ml to 174 1.0×10^2 pfu/ml using UTM media. Each dilution was tested in triplicate and UTM was used as negative control following previous work²⁶⁻²⁹. The LOD was defined as the lowest dilution where all the three 175 176 replicates were positive. DNA from the serial dilutions was extracted using the QiAamp96 Virus 177 Oiacube HT kit and viral copy numbers per mL (copies/mL) were calculated using a standard curve of 178 quantified synthetic DNA (G2R gene) in the QuantStudio 5 tested using the CDC PCR. Synthetic DNA 179 (Eurofins Genomics, UK) was re-hydrated in Tris-EDTA buffer and concentration quantified using 180 QubitTM SSDNA Quantification Assay kit (ThermoFisher, USA). Standard curve was prepared using 181 an eight 10-fold serial dilution series with 5 replicates per dilution.

182 **Statistical analysis**

183 The sensitivity and specificity of the index tests were calculated with 95% confidence interval in 184 comparison to both reference PCR assays, including stratification by cycle threshold (Ct) value. Prior the analysis, a normality test was performed using the Shapiro Wilk test (p<0.05). Differences between 185 186 the Ct values (expressed as mean± standard deviation [SD]) in sample groups were assessed using the 187 paired Student's t-test. Differences in the frequency of MPXV detection by sampling date were analysed 188 using Chi-squared test and Fisher's exact test. Statistical significance was set for a p < 0.05. The 189 statistical analysis was performed using GraphPad Prism version 8.0.0, GraphPad Software (Boston, 190 USA).

191 **Results**

192 **Clinical evaluation**

- 193 The demographic and clinical characteristics of the participants are shown in Table 1. The 16 positive
- 194 patients with mpox were assessed at the three hospitals during the study period. All individuals were
- 195 men (100%) with a mean age of 35.1 years (range 24-58 years). The median days from onset of
- 196 symptoms was 8 with the most common symptoms being skin lesions (100%), skin rushes (87.5%) and
- 197 fever (68,75%). The results shown in table 1 included only the mpox positive patients (n=16). The
- 198 negative cohort (COVID-19 patients) was not included in Table 1 as these were from a population not
- 199 suspected from MPXV infection.
- 200 Table 1. Clinical characteristics of mpox patients from UK used for the evaluation of both molecular
- 201 platforms.

Characteristic	
Age [mean (min-max), N]	35.1 (24-58), 16
Gender [%M, (n/N)]	100%; (16/16)
Days from symptom onset [median (Q1-Q3); N]	8 (4.25 - 12.75); 16
Days $< 0-3$ (n, %)	1, 6.25%
Days 4–7 (n, %)	6, 37.5%
Days 8+ (n, %)	9, 56,25%
Symptoms [% (n/N)]	
Skin lesions	100% (16/16)
Skin rashes	87.5% (14/16)
Fever	68.75% (11/16)
Flu like symptoms	25% (4/16)
Headache	25% (4/16)
Sore throat	25% (4/16)
Cough	6.25% (1/16)
Diarrhoea	6.25% (1/16)
Chest pain	0% (0/16)
Abdominal pain	0% (0/16)
Nausea	0% (0/16)
Vomiting	0% (0/16)
Painful Urination	0% (0/16)

203	Fourteen of the 23 URS and 25 of 30 SS collected from mpox positive patients were positive by the
204	CDC qPCR. When using the Sansure qPCR, 1 further URS (4.3%) and 4 SS (13%) were positive. The
205	mean Ct value when using the Sansure and CDC qPCR were 30.09 (\pm 5.70) and 27.54 (\pm 5.87),
206	respectively. The mean difference in Ct values between both tests had no significant difference for any

of the sample types (p-value= 0.34). As expected, all 32 UTM samples collected from the COVID-19

208 cohort were negative for MPXV using both reference qPCR tests.

209 The overall clinical sensitivity and specificity for the Xpert® Mpox assay using both sample types were 210 97.67% [95% CI 87.71 – 99.94%] and 88.57% [95% CI 73.26 – 96.80%] with the Sansure qPCR and 211 97.44% [95% CI 86.52 – 99.94%] and 74.42% [95% CI 58.83 – 86.48%] comparing to the CDC qPCR. 212 The values by sample type are found in Tables 2 and 3. The overall percentage of agreement was 90.3% 213 [95% CI 81.7–95.7%] and 91.5% [95% CI 83.2–96.5%], when using the Sansure qPCR and CDC 214 qPCR. Three URS were invalid with Xpert® Mpox assay (5.45%, 3/55) and all of SS were valid. 215 (Tables 2-3). The specificity was 83.78% [95% 78.20 - 100%] and 81.58% [95% CI 65.67 – 92.26%] 216 for URS using Sansure and CDC PCR. Specificity could not be accurately calculated for SS due to the 217 lack of negative specimens using the reference tests. 218 The overall sensitivity and specificity for the M10 MPX/OPX using both sample groups were 87.80% 219 [95% CI 73.80 – 95.92%] and 76.60% [95% CI 61.97 – 87.70%] and 94.29% [95% CI 80.84 – 99.30%] 220 and 86.67% [95% CI 73.21 – 94.95%] compared with the Sansure and CDC qPCR, respectively. The 221 values by sample type are found in Tables 2 and 3. The overall percentage of agreement was 91.3% 222 [95% CI 82.8 – 96.4%] and 95.0% [95% CI 87.7 – 98.6%] with the Sansure qPCR and CDC qPCR, 223 respectively. The specificity was 92.11% (78.62% - 98.34%) and 94.59% [95% CI 81.81 - 99.34%] 224 using URS compared to Sansure and CDC PCR, respectively. All SS were positive with both reference 225 assays except for 1 sample using the CDC PCR, therefore specificity could not be accurately calculated 226 for this sample type. Three URS (5.45%, 3/55) and 2 SS (6.66%, 2/30) were invalid using the M10 227 MPX/OPX.

- 228
- 229
- 230
- 231
- 232
- 233

Table 2. Results and clinical sensitivity and specificity of the Xpert[®] Mpox assay and M10 MPX/OPX

	Dogulta	Sansure qPCR			CDC qPCR		
	Results	Positive	Negative	Total	Positive	Negative	Total
Xpert [®] Mpox	Positive	15	6	21	14	7	21
	Negative	0	31	31	0	31	31
	Total*	15	37	52	14	38	52
	Clinical sensitivity (95% CI)	100% (78.20% - 100%)			100% (76.24% - 100%)		
	Ct <25 [95% CI, N]	100% (15.81% - 100%), 2			100% (39.76% - 100%), 4		
	Ct <35 [95% CI, N]	100% (69.15% - 100%), 10 100% (69.15% - 100%				%), 10	
	Ct <40 [95% CI, N]	100% (78.20% - 100%), 15			100% (76.84% - 100%), 14		
	Clinical specificity (95% CI)	83.78% (67.99% - 93.81%)			81.58% (65.67% - 92.26%)		
X40/X	Positive	10	2	12	10	2	12
	Negative	4	36	40	2	38	40
	Total*	14	38	52	12	40	52
	Clinical sensitivity (95% CI)	71.43% (41.90% - 91.61%)			71.43% (41.90% - 91.61%)		
Ξ	Ct <25 [95% CI, N]	100% (15.81% - 100%), 2			100% (15.81% - 100%), 2		
M10	Ct <35 [95% CI, N]	100% (66.37% - 100%), 9			100% (66.37% - 100%), 9		
	Ct <40 [95% CI, N]	71.43% (41.90% - 91.61%), 10			100% (69.15% - 100%), 10		
	Clinical specificity (95% CI)	92.11% (78.62% - 98.34%)			94.59% (81.81% - 99.34%)		

using upper-respiratory samples from mpox (n=23) and COVID-19 patients (n=32).

236

*Three samples were invalid with Xpert® Mpox and M10 MPX/OPX.

237

238 239

- 240 **Table 3.** Results and clinical sensitivity and specificity of the Xpert[®] Mpox assay and M10 MPX/OPX
- 241 assays using skin lesion swabs (SS) (n=30).

	Dearrilda	Sansure qPCR			CDC qPCR			
	Results	Positive	Negative	Total	Positive	Negative	Total	
Xpert[®] Mpox	Positive	27	2	29	24	4	28	
	Negative	1	0	1	1	1	2	
	Total	28	2	30	25	5	30	
	Clinical sensitivity (95% CI)	96.43% (81.65% - 99.91%)			96% (79.65% - 99.90%)			
	Ct <25 [95% CI, N]	100% (63.06% - 100%), 8			100% (73.54% - 100%), 12			
	Ct <33 [95% CI, N]	100% (63.03% - 100%), 17			100% (83.16% - 100%), 20			
	Ct <40 [95% CI, N]	96.43% (81.65% - 99.91%), 30			96% (79.65% - 99.90%), 30			
	Clinical specificity (95% CI)*	NA			NA			
XdO)	Positive	26	1	27	23	4	27	
	Negative	1	0	1	0	1	1	
	Total**	27	1	28	23	5	28	
X	Clinical sensitivity (95% CI)	96.30% (81.03% - 99.91%)		100% (85.18% - 100%)				
Ξ	Ct <25 [95% CI, N]	100% (69.15% - 100%), 10		100% (73.54% - 100%), 12				
M10	Ct <33 [95% CI, N]	100% (79.41% - 100%), 16		100% (82.35% - 100%),19				
	Ct <40 [95% CI, N]	96.30% (81.03% - 99.91%), 28		100% (85.18% - 100%), 23				
	Clinical specificity (95% CI)*	NA		NA				

*Only one SS was negative using the CDC qPCR so specificity was not calculated for this sample type. **Two SS were invalid with M10 MPX/OPX assay.

All rights reserved. No reuse allowed without permission.

245 The Ct values of paired samples were also compared and evaluated for each qPCR reference assay and 246 POC index NAAT (Figures 1A-1D). Nine, 10, 10 and 7 URS and SS paired samples were positive for 247 Sansure qPCR, CDC, Xpert Mpox and M10 MPX/OPX. No significant differences in Ct values were 248 found between URS and SS sample groups when using the Sansure qPCR, CDC and M10 MPX/OPX 249 (p-value=0.54, 0.73 and 0.37, respectively). The analysis of the paired samples using the Xpert[®] Mpox 250 assay showed higher Ct values in the URS group compared to the SS group (p-value=0.03) with mean 251 Ct values of $30.58 (\pm 5.48)$ and $24.75 (\pm 5.98)$ for URS and SS.

- 252
- 253



272 Figure 1. Boxplot of the Ct values from paired URS and SS tested by A. Sansure qPCR (n=9), B. CDC 273 qPCR (n=10), C. Xpert[®] Mpox (n=10) and D. M10 MPX/OPX (n=7). The whiskers show the maximum 274 and minimum values and the vertical line the median. There was a significant difference (p-value < 0.05) 275 between paired URS and SS when evaluated with the Xpert[®] Mpox assays with higher Ct values in the 276 URS group. 277 Overall, the higher positivity rates for detecting MPXV DNA in clinical samples was the Xpert[®] Mpox 278 (n=50/53), followed by Sansure qPCR (n=44/53), CDC qPCR (n=41/53) and M10 MPX/OPX (n=37/53) 279 and this difference was statistically significant for URS (p=0.015) but not for SS (p=0.692). 280 The number of MPXV positive samples depending on the sampling collection day from onset of symptoms 281 was evaluated for all samples and all PCR tests (Figure 2). URS collected from MPXV patients more than 3 282 days after the symptom onset were less likely to have detectable levels of virus using all PCR assays used in 283 the study (Sansure p = 0.017, CDC p = 0.033, Xpert[®] Mpox p = 0.04 and M10 MPX/OPX p = 0.014). 284 URS collected from MPXV patients more than 2 days after the symptom onset were less likely to present 285 the virus to detectable levels by Sansure (p = 0.014) and M10 MPX/OPX (p = 0.007). This was not significant for the SS for any collection date (all p values > 0.05) except for M10 MPX/OPX among SS 286 287 collected more than 5 days after onset of symptoms (p = 0.022).







291 The Ct values as a proxy for viral loads were analysed by sampling day from onset of symptoms and higher 292 Ct values were observed as the sampling day increased in URS for Sansure qPCR (p = 0.0093, r=0.5895%293 0.12-0.84) CDC qPCR (p = 0.0444, r=0.45 95% -0.08-0.8) and Xpert® Mpox (p = 0.0024, r=0.59 95% 0.21-

294 0.81) but not for M10 (p = 0.1752, r=0.3095% -0.33-0.74). No correlation was observed between viral loads

295 and sampling date in SS (Figure 3).

medRxiv preprint doi: https://doi.org/10.1101/2024.09.09.24313234; this version posted September 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



311 Figure 3: Plot of the Ct values of the four platforms by collection day from symptom onset using SS 312 (n=30) and URS (n=23) from MPXV positive patients. Data points are individual clinical samples, with 313 SS sampling from different lesions.

314

315 **Analytical evaluation**

- The LOD was 1.0x10¹ pfu/mL for Xpert[®] Mpox and M10 MPX/OPX, 1.0x10² pfu/mL for Sansure qPCR 316
- 317 and 1.0×10^3 pfu/mL for the CDC qPCR (Figure 4). The approximated viral copy number of the LOD
- 318 was calculated for all the assays and was at $\approx 1.31 \times 10^2$ copies/mL for Xpert[®] Mpox and M10 MPX/OPX,
- $\approx 1.3 \times 10^3$ copies/mL for Sansure qPCR and $\approx 1.3 \times 10^4$ copies/mL for CDC qPCR. 319

320



321

322 Figure 4: Relationship between Ct values and viral load using both qPCR reference assays and POC 323 index NAATs.

324 Discussion

The primary aim of this study was to evaluate the diagnostic performance of two POC NAAT, Xpert[®] 325 326 Mpox and M10 MPX/OPX. Rapid molecular diagnostic tests offer several advantages to laboratory-327 based PCR methods such as minimal sample processing, automated results readout and rapid availability of results to speed up clinical decision-making for timely management in outbreak 328 329 situations, hence it is critical to assess their diagnostic accuracy.

The Xpert[®] Mpox test is designed to be used with lesion swabs³⁰. Previous studies have evaluated the 330 331 accuracy for detection of MPXV in crusts and vesicular swabs samples in DRC showing a sensitivity of 98% and a specificity of 100% in both sample types³¹ and in oropharyngeal, lesions and anal swabs 332 333 in Georgia, USA with a sensitivity of 100% and specificity of 83.3% to 90.9% depending on sample 334 type³². The published data aligns with our results when using the platform with both lesion and upper-335 respiratory swabs. In this study, the Xpert[®] Mpox detected MPXV DNA from clinical samples that 336 were negative by the reference lab-based qPCR Sansure and CDC, suggesting greater sensitivity. The 337 greater sensitivity of the Xpert[®] Mpox compared to a reference lab-based MPXV PCR has also been observed elsewhere³². This could be due to the larger sample volume used in the Xpert[®] Mpox (300 µl) 338

compared to the volume used in the lab-based qPCR tests (2.5µl and 10µl of 50µl eluted DNA extracted
from 200µl of UTM for CDC and Sansure respectively). The GeneXpert platform has been widely used
for the detection of several infectious diseases, including SARS-CoV-2, *Mycobacterium tuberculosis*with rifampicin resistance, methicillin-resistant *Staphylococcus aureus*, and Ebola virus disease also
showing high sensitivity and specificity³³⁻³⁵.

344 The M10 MPX/OPX can be used on different specimen types such as skin lesion material, whole blood, oropharyngeal swabs and plasma³⁶. Compared to Xpert[®] Mpox, sensitivity was lower despite of 345 346 manufacturer claims of having the same analytical LOD (100 copies/mL) as the Sansure reference test. 347 The M10 MPX/OPX assay is for research use and skin lesion material, whole blood, oropharyngeal 348 swabs and plasm. In this study, the M10 MPX/OPX platform detected less MPXV positive samples 349 than the other tests, suggesting lower sensitivity. A previous study evaluating the diagnostic accuracy 350 of the M10 MPX/OPX test, showed lower sensitivity compared to the lab-based qPCR RealStar® OPX-351 1^{37} , aligning with the results obtained in the present study. During the COVID-19 pandemic, SD 352 Biosensor developed the M10 SARS-CoV-2, a molecular in vitro diagnostic assay able to detect SARS-CoV-2 viral RNA that also uses the M10 platform as the MPX/OPX assay³⁸ with 100% sensitivity and 353 354 100% specificity^{39,40}.

355 The WHO recommends the use of skin lesions for laboratory confirmation of MPXV infection 356 whenever possible¹⁵. Our study indicates that URS can be used as a reliable alternative sample type to 357 SS for patients sampled within the first 3 days of symptoms onset. This presents an advantage as the 358 use of URS for POC testing in suspected cases can be used to diagnose Mpox in patients without typical 359 skin lesions including those who may be in the prodromal phase of the disease when skin lesions have not appeared yet. The use of URS for Mpox diagnosis early in the disease can be particularly beneficial 360 for monitoring contacts of positive cases for rapid detection, isolation and patient management. 361 362 However, the use of SS for MPXV detection was more robust among samples collected from patients 363 regardless of the time from symptom onset, except for M10 MPX/OPX that showed poor sensitivity in 364 skin lesion swabs collected from patients more than 5 days after symptom onset. This provides key 365 information for choosing the adequate sample type and tests, specifically for when patients present to 366 the clinic several days after the disease onset. The Ct value of paired URS and SS showed no significant

367 differences except for the Xpert[®] Mpox platform. These results differ from previous studies where they 368 observed that lesion samples presented a viral load 3 orders of magnitude higher than URS⁴¹ and suggest 369 that URS testing offers no additional information for the diagnosis in individuals presenting skin 370 lesions⁴¹⁻⁴³. The lower sensitivity obtained in URS among these collected from patients more than 3 371 days after symptom onset can be attributed to viral clearance occurring earlier in the oropharynx sample 372 than in skin lesions⁴⁴.

373 Based on the target products profile (TPP) for tests used for mpox diagnosis within health care settings 374 and laboratories published by the WHO, the minimal and optimal clinical sensitivity should be $\geq 95\%$ 375 and \geq 97%, and minimal and optimal clinical specificity should be \geq 97% compared to a reference 376 molecular method⁴⁵. The results obtained using the Xpert[®] Mpox assay met the minimal clinical 377 sensitivity using SS and optimal sensitivity using URS regardless of the qPCR used as reference 378 method. In the case of the MPX/OPX assay, the minimal and optimal clinical sensitivity was met with 379 SS when compared to Sansure and CDC qPCR reference tests however the sensitivity using URS did 380 not fulfil the minimum clinical sensitivity regardless of the qPCR reference assay used. False positive 381 results in the index tests have been attributed to lower sensitivity of the reference test compared to the index tests since all the "false positive" results were obtained from MPXV positive patients and both 382 383 Xpert[®] Mpox and M10 MPX/OPX had a lower LOD than the reference tests used in this study. This is 384 of importance as reference lab-based qPCR tests such as the widely used CDC protocol may fail to 385 diagnose true MPXV positive samples, and a composite reference standard should be determined.

The WHO recommends using laboratory-based nucleic acid amplification testing (NAAT) to confirm an MPXV infection¹⁵. The primers and probes used in the current MPXV generic qPCR test created by the CDC²¹ differ significantly due to genetic variations in >1000 available sequenced MPXV genomes impacting on the sensitivity and specificity of the test⁴⁶. This could be a possible explanation of the higher LOD, and consequently lesser number of positive samples detected with the CDC qPCR compared with Sansure qPCR.

In this study we used frozen samples due to low prevalence causing difficulties for fresh samples and
 prospective evaluation. However, the IFU of both index tests indicate they can detect MPXV in frozen

394 samples as well as samples stored at 4° C and room temperature³⁰. The lack of negative skin lesion swab

395 specimens is a limitation of the study as we could not calculate specificity using this sample type.

396 In conclusion, the Xpert® Mpox demonstrated the greatest diagnostic accuracy for POC testing and the

397 use of URS as alternative sample type to skin lesions have been shown to perform well in samples

398 collected within 3 days from onset symptoms. This study adds important insights on diagnostics of

399 Mpox.

400 Author contributions

401 The study was conceived and designed by AICA, JD and DE. Laboratory work was conducted by AS,

402 JP, YH, DW, NK, CTW and ARR, with supervision by AICA and TE. Data collections were conducted

403 by AS, JP, YH, HH, NK, and SG. Data analysis and interpretation were conducted by ARR and AICA.

404 The initial manuscript was prepared by ARR and AICA. Funding was acquired by AICA, the CONDOR

405 steering group and ISARIC CPP investigators. Oversight of participant recruitment was performed by

406 AICA, the CONDOR steering group and ISARIC CPP investigators. All authors edited and approved

407 the final manuscript.

408 **Declarations of interests**

409 DE had no role on the data collection, analysis and interpretation. The other authors have no interests

410 to declare. The views expressed are those of the authors and not necessarily those of the funding bodies.

411 Acknowledgements

We acknowledge the participants for volunteering for this study. We thank all the CRN, research nurses and clinical research fellows for supporting us with the sample collection and recruitment. We also would like to extend our acknowledgements to the wider FIND team involved in this study, specifically to Audrey Albertini, Juvenal Nkeramahame, Michael Otieno and Ryan Ruiz.

CONDOR steering group: A. Joy Allen, Julian Braybrook, Peter Buckle, Eloise Cook, Paul Dark,
Kerrie Davis, Gail Hayward, Adam Gordon, Anna Halstead, Charlotte Harden, Colette Inkson, Naoko
Jones, William Jones, Dan Lasserson, Joseph Lee, Clare Lendrem, Andrew Lewington, Mary Logan,
Massimo Micocci, Brian Nicholson, Rafael Perera-Salazar, Graham Prestwich, D. Ashley Price,
Charles Reynard, Beverley Riley, John Simpson, Valerie Tate, Philip Turner, MarkWilcox, Melody
Zhifang.

ISARIC CCP investigators: Dr Mike Beadsworth, Dr Ingeborg Welters, Dr Lance Turtle, Dr Jane
Minton, Karl Ward, Dr Elinor Moore, Dr Elaine Hardy, Dr Mark Nelson, Dr Jane Minton, Karl Ward,
Dr David Brealey, Dr Ashley Price, Dr Brian Angus, Dr Graham Cooke and Dr Oliver Koch.

425 Funding

426 This work was funded as part of FIND's work as coconvener of the diagnostics pillar of the Pandemic 427 Threats Programme. ISARIC4 was funded from the National Institute for Health Research [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059] and by Liverpool Pandemic Institute 428 429 and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in 430 Emerging and Zoonotic Infections at University of Liverpool in partnership with UK Health Security 431 Agency (UK-HSA), in collaboration with Liverpool School of Tropical Medicine and the University of 432 Oxford [NIHR award 200907], Wellcome Trust and Department for International Development 433 [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], and Liverpool 434 Experimental Cancer Medicine Centre for providing infrastructure support for this research (Grant 435 Reference: C18616/A25153).

The FALCON study was funded by the National Institute for Health Research, Asthma United Kingdom, and the British Lung Foundation. This work is partially funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections (200907), a partnership between the United Kingdom Health Security Agency (UKHSA), The University of Liverpool, The University of Oxford, and LSTM.

All rights reserved. No reuse allowed without permission.

Parker, S., Schultz, D., Meyer, H. & Buller, R. Smallpox and Monkeypox Viruses. (2014).

442 **References**

1

- 444 2 Titanji, B. K., Tegomoh, B., Nematollahi, S., Konomos, M. & Kulkarni, P. A. in Open forum 445 infectious diseases. ofac310 (Oxford University Press). 446 von Magnus, P., Andersen, E. K., Petersen, K. B. & Birch Andersen, A. A pox-like disease in 3 447 cynomolgus monkeys. (1959). 448 Breman, J. G., Steniowski, M., Zanotto, E., Gromyko, A. & Arita, I. Human monkeypox, 1970-4 449 79. Bulletin of the World Health Organization 58, 165 (1980). 450 5 Organization, W. H. WHO recommends new name for monkeypox disease, 2022). 451 6 Organization, W. H. 2022 Mpox (Monkeypox) Outbreak: Global Trends. World Health 452 Organization (2022). 7 453 Pan, D. et al. Transmission of monkeypox/mpox virus: A narrative review of environmental, 454 viral, host, and population factors in relation to the 2022 international outbreak. Journal of 455 Medical Virology 95, e28534 (2023). 456 8 Adler, H. et al. Clinical features and management of human monkeypox: a retrospective 457 observational study in the UK. The Lancet Infectious Diseases 22, 1153-1162 (2022). 458 9 Organization, W. H. Multi-country monkeypox outbreak: situation update. (2022). 459 10 Agency, U. H. S. Vol. Technical Brief# 4 (United Kingdom Health Security Agency, 2022). 460 11 Girometti, N. et al. Demographic and clinical characteristics of confirmed human monkeypox 461 virus cases in individuals attending a sexual health centre in London, UK: an observational 462 analysis. The Lancet Infectious Diseases 22, 1321-1328 (2022). 463 12 McCollum, A. M. & Damon, I. K. Human monkeypox. Clinical infectious diseases 58, 260-464 267 (2014). 465 13 Prevention, C. f. D. C. a. Mpox: signs and symptoms, 2024). 466 14 Organization, W. H. Clinical management and infection prevention and control for monkeypox: 467 interim rapid response guidance, 10 June 2022. (World Health Organization, 2022). 468 15 Organization, W. H. in Diagnostic testing for the monkeypox virus (MPXV): interim guidance, 469 *9 November 2023* (2023).470 Organization, W. H. WHO Director-General declares mpox outbreak a public health emergency 16 471 of international concern, 2024). 472 17 Agency, U. F. a. D. A. F. Monkeypox (mpox) Emergency Use Authorizations for Medical 473 Devices, 2024). 474 18 FIND. Outbreaks tests directory, 2024). 475 19 Gavina, K., Franco, L. C., Khan, H., Lavik, J.-P. & Relich, R. F. Molecular point-of-care devices 476 for the diagnosis of infectious diseases in resource-limited settings-A review of the current 477 landscape, technical challenges, and clinical impact. Journal of Clinical Virology 169, 105613 478 (2023).479 20 Hardwick, C. S. H. Clinical characterisation protocol for severe emerging infection, 2020). 480 21 Prevention, C. f. D. C. a. Test Procedure: Monkeypox Virus Generic Real-time PCR Test., 2022). 481 22 Michel, J. et al. Evaluation of 11 commercially available PCR kits for the detection of 482 monkeypox virus DNA, Berlin, July to September 2022. Eurosurveillance 27, 2200816 (2022). 483 23 Li, Y., Zhao, H., Wilkins, K., Hughes, C. & Damon, I. K. Real-time PCR assays for the specific 484 detection of monkeypox virus West African and Congo Basin strain DNA. Journal of 485 virological methods 169, 223-227 (2010). 486 24 Li, Y., Olson, V. A., Laue, T., Laker, M. T. & Damon, I. K. Detection of monkeypox virus with 487 real-time PCR assays. Journal of Clinical Virology 36, 194-203 (2006). 488 Pawar, S. D. et al. Replication of SARS-CoV-2 in cell lines used in public health surveillance 25 489 programmes with special emphasis on biosafety. Indian Journal of Medical Research 155, 129-490 135 (2022). 491 26 Byrne, R. L. et al. Comparison of the analytical and clinical sensitivity of thirty-four rapid 492 antigen tests with the most prevalent SARS-CoV-2 variants of concern during the COVID-19 493 pandemic in the UK. medRxiv, 2023.2007. 2024.23293072 (2023).
- 49427Cubas-Atienzar, A. I. *et al.* Limit of detection in different matrices of 19 commercially available495rapid antigen tests for the detection of SARS-CoV-2. *Scientific reports* 11, 18313 (2021).

All rights reserved. No reuse allowed without permission.

- 496 28 Kontogianni, K. *et al.* Analytical evaluation of thirty-two severe acute respiratory syndrome 2
 497 lateral flow antigen tests demonstrates sensitivity remains with the SARS-CoV-2 Gamma
 498 lineage. *Revista da Sociedade Brasileira de Medicina Tropical* 55, e0016-2022 (2022).
- 499 29 Kontogianni, K. *et al.* Lateral flow antigen tests can sensitively detect live cultured virus of the
 500 SARS-CoV-2 B1. 1.7 lineage. *Journal of Infection* 83, e1-e4 (2021).
- 501 30 Innovation, C. (2023).
- 502 31 Li, D. *et al.* Evaluation of the GeneXpert for human monkeypox diagnosis. *The American* 503 *journal of tropical medicine and hygiene* **96**, 405 (2017).
- Damhorst, G. L. *et al.* Performance of the Xpert[™] Mpox PCR assay with oropharyngeal, anorectal, and cutaneous lesion swab specimens. *Journal of Clinical Virology* **171**, 105659 (2024).
- 507 33 Pan, Z.-Y. *et al.* Pooled Analysis of the Accuracy of Xpert Ebola Assay for Diagnosing Ebola
 508 Virus Infection. *BioMed Research International* 2021 (2021).
- 509 34 Evans, C. A. GeneXpert—a game-changer for tuberculosis control? *PLoS medicine* **8**, e1001064 (2011).
- Standard Sta
- 515 36 Biosensor, S. STANDARD M10 MPX/OPX.
- 516 37 Mancon, A. *et al.* Evaluation of analytical performance of the STANDARDTM M10
 517 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox
 518 virus. *Emerging Microbes & Infections* 13, 2337666 (2024).
- 519 38 Biosensor, S. (2023).
- 52039Parakatselaki, M.-E., Alexi, G., Zafiropoulos, A. & Sourvinos, G. Evaluation of521STANDARDTM M10 SARS-CoV-2 assay as a diagnostic tool for SARS-CoV-2 in522nasopharyngeal or oropharyngeal swab samples. Journal of Clinical Virology Plus 3, 100129523(2023).
- Ham, S. Y. *et al.* Performance of STANDARD[™] M10 SARS-CoV-2 Assay for the Diagnosis
 of COVID-19 from a Nasopharyngeal Swab. *Infection & Chemotherapy* 54, 360 (2022).
- 526 41 Tarín-Vicente, E. J. *et al.* Clinical presentation and virological assessment of confirmed human
 527 monkeypox virus cases in Spain: a prospective observational cohort study. *The Lancet* 400,
 528 661-669 (2022).
- 529 42 Ouafi, M. *et al.* Oropharyngeal samples versus lesion specimens at diagnosis in patients
 530 infected with monkeypox virus in Northern France. *Journal of Medical Virology* 95, e28276
 531 (2023).
- 43 Palich, R. *et al.* Viral loads in clinical samples of men with monkeypox virus infection: a French
 533 case series. *The Lancet Infectious Diseases* 23, 74-80 (2023).
- 53444Suñer, C. *et al.* Viral dynamics in patients with monkeypox infection: a prospective cohort study535in Spain. The Lancet Infectious Diseases 23, 445-453 (2023).
- 536 45 Organization, W. H. *Target product profiles for tests used for mpox (monkeypox) diagnosis*.
 537 (World Health Organization, 2023).
- Wu, F., Oghuan, J., Gitter, A., Mena, K. D. & Brown, E. L. Wide mismatches in the sequences of primers and probes for monkeypox virus diagnostic assays. *Journal of Medical Virology* 95, e28395 (2023).